Pharmacogenetics of nonsteroidal anti-inflammatory drugs

Pharmacogenomics Journal

Volumn 12, Issue 6, 2012, Pages 462-467

  Wyatt, J E ^a   Pettit, W L ^a   Harirforoosh, S ^a  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

cyclooxygenase; NSAIDs; pharmacogenetics; polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; DICLOFENAC EPOLAMINE; DICLOFENAC POTASSIUM; DIFLUNISAL; ETODOLAC; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC TROMETAMOL; LUMIRACOXIB; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; METOPROLOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; ROFECOXIB; SALICYLATE SODIUM; SALSALATE; SULINDAC; TENOXICAM; TOLMETIN; UNINDEXED DRUG;

ALLELE; ANALGESIA; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; BLEEDING TIME; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG INDUSTRY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENZYME BLOOD LEVEL; ENZYME INACTIVATION; ENZYME INHIBITION; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENETIC ORGANIZATION; GENETIC SCREENING; GENETIC VARIABILITY; GOUT; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HETEROZYGOTE; HORMONE SYNTHESIS; HUMAN; HUMAN GENOME PROJECT; IN VITRO STUDY; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OSTEOARTHRITIS; PAIN; PATIENT CARE; PHARMACOGENETICS; PRIORITY JOURNAL; PROCESS MODEL; PROCESS OPTIMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ULCER; TOOTH PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; DICLOFENAC; HUMANS; IBUPROFEN; INDOMETHACIN; PHARMACOGENETICS; PYRAZOLES; SULFONAMIDES;

EID: 84870061138     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.40     Document Type: Review

References (64)

1. Palmer SN, Giesecke NM, Body SC, Shernan SK, Fox AA, Collard CD. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 2005; 102: 663-671.
2. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-459.
3. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics, 12th edn. McGraw-Hill: New York, 2011.
4. Cavallari LH, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A Pathophysiologic Approach, 7th edn. McGraw-Hill Medical: New York, 2008, pp 31-47.
5. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-933.
6. Harirforoosh S, Fleckenstein L, Mahajan P, Aruoma OI, Huang Y, Moridani M. The importance of including topics related to pharmacogenetics, pharmacogenomics, and medical genetics in the pharmacy curriculum. Am J Pharm Educ 2009; 73: 114.
7. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
8. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal antiinflammatory drugs and heart failure. Drugs 2003; 63: 525-534.
9. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001; 299: 468-476.
10. Yun HR, Lee SO, Choi EJ, Shin HD, Jun JB, Bae SC. Cyclooxygenase-2 polymorphisms and risk of rheumatoid arthritis in Koreans. J Rheumatol 2008; 35: 763-769.
11. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-741.
12. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009; 8: 669-681.
13. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-598.
14. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 2001; 10: 89-98.
15. Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007; 8: 2235-2245.
16. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-518.
17. Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57: 729-735.
18. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30: 385-390.
19. Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009; 5: 607-620.
20. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.
21. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99: 410-414.
22. American Society of Hospital Pharmacists. AHFS Drug Information. Published by authority of the Board of Directors of the American Society of Health-System Pharmacists: Bethesda, MD, 2009.
23. He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 2011; 18: 667-713.
24. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003; 74: 130-137.
25. Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structureactivity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009; 16: 3480-3675.
26. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54: 423-429.
27. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11: 223-235.
28. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42: 283-292.
29. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13: 473-480.
30. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009; 136: 2127-2136 e2121.
31. Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G et al. The cyclooxygenase 2 genetic variant 765G4C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 2006; 80: 621-632.
32. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-714.
33. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-684.
34. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674.
35. Furst DE, Ulrich RW. Nonsteroidal Anti-inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopiod Analgesics, & Drugs Used in Gout. In: Katzung BG. Basic and Clinical Pharmacology, 10th edn. McGraw-Hill Medical: New York, 2007, pp 573-598.
36. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
37. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
38. Chen Y, Kuehl GE, Bigler J, Rimorin CF, Schwarz Y, Shen DD et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genomics 2007; 17: 571-579.
39. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26: 261-266.
40. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33: 1567-1575.
41. Wynne HA, Long A, Nicholson E, Ward A, Keir D. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? Br J Clin Pharmacol 1998; 45: 405-408.
42. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51: 627-630.
43. Kumar A, Mann HJ, Remmel RP. Simultaneous analysis of cytochrome P450 probesdextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 287-293.
44. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003; 58: 791-794.
45. Qayyum A, Najmi MH, Farooqi ZU. Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method. J Chromatogr Sci 2011; 49: 108-113.
46. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-154.
47. Geisslinger G, Stock KP, Loew D, Bach GL, Brune K. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 603-607.
48. Leemann TD, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-195.
49. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54: 33-41.
50. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72: 62-75.
51. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-210.
52. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 71-80.
53. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-349.
54. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-367.
55. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76: 119-127.
56. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
57. Carbonell N, Verstuyft C, Massard J, Letierce A, Cellier C, Deforges L et al. CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin Pharmacol Ther 2010; 87: 693-698.
58. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76: 18-26.
59. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
60. Peiro AM, Novalbos J, Zapater P, Moreu R, Lopez-Rodriguez R, Rodriguez V et al. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol Res 2009; 59: 62-68.
61. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281.
62. Blanco G, Martinez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008; 18: 37-43.
63. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 2006; 79: 407-418.
64. Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11: 843-864.